Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Operating Leases (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed Operating Leases for 7 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases changed 0.03% to $3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.5 million, a 0.03% change, with the full-year FY2025 number at $3.5 million, changed 0.03% from a year prior.
  • Operating Leases was $3.5 million for Q4 2025 at Akebia Therapeutics, up from $671000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $37.7 million in Q1 2022 to a low of $671000.0 in Q2 2025.
  • A 5-year average of $19.5 million and a median of $20.3 million in 2021 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: surged 74.21% in 2022, then crashed 89.35% in 2025.
  • Akebia Therapeutics' Operating Leases stood at $33.7 million in 2021, then decreased by 14.07% to $29.0 million in 2022, then plummeted by 69.11% to $8.9 million in 2023, then plummeted by 60.36% to $3.5 million in 2024, then rose by 0.03% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Operating Leases are $3.5 million (Q4 2025), $671000.0 (Q2 2025), and $3.5 million (Q4 2024).